Identification
- Generic Name
- Sutilain
- DrugBank Accession Number
- DB09379
- Background
Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from Bacillus subtilis and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000 casein units of proteolytic activity.2 Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.3
- Type
- Biotech
- Groups
- Approved, Withdrawn
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Sutilaina
- Sutilaines
- Sutilains
- External IDs
- BAX 1515
- BAX-1515
Pharmacology
- Indication
Sutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseases.2
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Reports indicated that sutilain exhibited a rapid and effective debridement when used for the treatment of burns, decubiti and traumatic wounds. In the case of peripheral vascular ulcerations, it did not respond in a predictable manner.1 When used, sutilain caused a rapid dissolution of the surface of the treated skin zone. However, a graftable wound bed as achieved no more rapidly than if saline soaks had been used since the enzyme appears to be ineffective in removing deep dermal elements and necrotic fat.4
- Mechanism of action
Sutilain is a proteolytic enzyme that dissolves necrotic tissue and hyaluronidase.1
- Absorption
Sutilain is not absorbed.
- Volume of distribution
This pharmacokinetic parameter is not relevant.
- Protein binding
This pharmacokinetic parameter is not relevant.
- Metabolism
This pharmacokinetic parameter is not relevant.
- Route of elimination
This pharmacokinetic parameter is not relevant.
- Half-life
This pharmacokinetic parameter is not relevant.
- Clearance
This pharmacokinetic parameter is not relevant.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The toxicity has not been determined.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Travase Ointment 82000 Casein Units/gm Ointment 82000 unit / g Topical Boots Pharmaceuticals Ltd. 1987-12-31 1996-09-09 Canada 
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 2PU6O23V1G
- CAS number
- 12211-28-8
References
- General References
- Coopwood TB: Evaluation of a topical enzymatic debridement agent--sutilains ointment: a preliminary report. South Med J. 1976 Jul;69(7):834-6. [Article]
- Kokate C., Purohit A. and Gokhale S. (2008). Pharmacognosy (42nd ed.). Pragati Book House. [ISBN:978-81-96396-15-2]
- FDA approval [Link]
- US Army Annual progress report [Link]
- External Links
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Ointment Topical 82000 unit / g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at November 30, 2015 19:10 / Updated at February 03, 2022 06:26